


AstraZeneca launches Trastuzumab deruxtecan for HER-2 positive metastatic breast cancer patients in India

03 January 2024 | News

Introduction of Trastuzumab deruxtecan is supported by positive results from the DESTINY-Breast03 trial



AstraZeneca India Pharma has launched *Trastuzumab deruxtecan*, therapy tailored for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer for those who have previously received an anti-HER2 regimen.

Developed in collaboration with Daiichi Sankyo, *Trastuzumab deruxtecan* is a specifically engineered HER2-directed antibody drug conjugate (ADC).

The global burden of breast cancer, identified by the World Health Organization (WHO) as the most diagnosed cancer, exceeded 2 million cases in 2020. In India, the incidence of breast cancer has surged by a significant 40% over the past 25 years. Addressing a critical medical need, *Trastuzumab deruxtecan* is a beacon of hope for patients confronting HER2-positive metastatic breast cancer.

The introduction of *Trastuzumab deruxtecan* is supported by positive results from the DESTINY-Breast03 trial, a global Phase III study. Primary results, published in The New England Journal of Medicine, reveal a remarkable 72% reduction in the risk of disease progression or death compared to trastuzumab emtansine (T-DM1).

AstraZeneca received (DCGI) in May 2023.	approval to impor	t and market <i>Tra</i> s	stuzumab deruxi	tecan from the Dru	g Controller	General of India